Capasso Raffaele, Izzo Angelo A, Capasso Francesco, Romussi Giovanni, Bisio Angela, Mascolo Nicola
Department of Experimental Pharmacology, University of Naples "Federico II", via D. Montesano 49, 80131 Naples, Italy.
Planta Med. 2004 Apr;70(4):375-7. doi: 10.1055/s-2004-818954.
This study was aimed to investigate the effect of 3,4 secoisopimara-4(18),7,15-trien-3-oic acid (compound 1) isolated from the aerial parts of Salvia cinnabarina, on upper gastrointestinal transit in mice in vivo. Compound 1 (10 - 100 mg/kg, i. p.) dose-dependently delayed gastrointestinal motility. Pretreatment ( i. p.) of mice with hexamethonium (10 mg/kg), naloxone (2 mg/kg), N(G)-nitro- L-arginine-methyl ester ( L-NAME) (25 mg/kg) or yohimbine (1 mg/kg) did not modify the inhibitory effect of compound 1 (50 mg/kg). However, the L-type Ca (2+) channel verapamil (5 mg/kg, i. p.) significantly reduced the antimotility effect of compound 1 (50 mg/kg). These results suggest that compound 1 inhibits gastrointestinal motility in mice. The effect could involve, at least in part, L-type Ca (2+) channels.
本研究旨在探讨从朱唇地上部分分离得到的3,4-裂环异海松-4(18),7,15-三烯-3-酸（化合物1）对小鼠体内上消化道转运的影响。化合物1（10 - 100毫克/千克，腹腔注射）剂量依赖性地延迟胃肠蠕动。用六甲铵（10毫克/千克）、纳洛酮（2毫克/千克）、N(G)-硝基-L-精氨酸甲酯（L-NAME）（25毫克/千克）或育亨宾（1毫克/千克）对小鼠进行预处理（腹腔注射），并未改变化合物1（50毫克/千克）的抑制作用。然而，L型钙通道阻滞剂维拉帕米（5毫克/千克，腹腔注射）显著降低了化合物1（50毫克/千克）的抗蠕动作用。这些结果表明化合物1抑制小鼠胃肠蠕动。该作用可能至少部分涉及L型钙通道。
